Company Analysis
Sign in

Molecular Partners AG (MOLN)

Nasdaq: MOLN · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.3
◀ Past 5.7● Present 5.4▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueCHF 0.00-100.0%
Net income-CHF 61.7M-14.1%
Earnings per shareCHF -1.65-3.8%
Operating cash flow-CHF 51.3M+13.5%
CashCHF 82.7M+29.4%
Debtn/a
Shareholders’ equityCHF 80.3M-43.3%
Shares, diluted37.3M+9.5%
Return on equity-76.7%
The recordfrom its filings
Filings in 202616
Newest filingOct 29 · 6-K
Annual reportMar 12, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 monthsn/a
Insider buys, 12 monthsn/a
Patents granted23
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in CHF. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton MOLN · research, not advice